|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NORAD |
Gene summary for NORAD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NORAD | Gene ID | 647979 |
| Gene name | non-coding RNA activated by DNA damage | |
| Gene Alias | LINC00657 | |
| Cytomap | 20q11.23 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 647979 | NORAD | PTCwithHT_8 | Human | Thyroid | HT | 2.68e-05 | -5.43e-01 | 0.0351 |
| 647979 | NORAD | PTCwithoutHT_2 | Human | Thyroid | PTC | 3.54e-09 | -6.02e-01 | 0.0419 |
| 647979 | NORAD | PTCwithoutHT_7 | Human | Thyroid | PTC | 1.35e-03 | -6.68e-01 | 0.0381 |
| 647979 | NORAD | male-WTA | Human | Thyroid | PTC | 5.62e-75 | 4.66e-01 | 0.1037 |
| 647979 | NORAD | PTC01 | Human | Thyroid | PTC | 7.37e-07 | 1.71e-01 | 0.1899 |
| 647979 | NORAD | PTC04 | Human | Thyroid | PTC | 6.04e-12 | 6.28e-01 | 0.1927 |
| 647979 | NORAD | PTC05 | Human | Thyroid | PTC | 1.13e-26 | 1.52e+00 | 0.2065 |
| 647979 | NORAD | PTC06 | Human | Thyroid | PTC | 1.38e-47 | 1.47e+00 | 0.2057 |
| 647979 | NORAD | PTC07 | Human | Thyroid | PTC | 6.47e-58 | 1.26e+00 | 0.2044 |
| 647979 | NORAD | ATC08 | Human | Thyroid | ATC | 3.40e-08 | -3.15e-01 | 0.0541 |
| 647979 | NORAD | ATC09 | Human | Thyroid | ATC | 7.12e-12 | 6.88e-02 | 0.2871 |
| 647979 | NORAD | ATC12 | Human | Thyroid | ATC | 2.41e-33 | 1.15e+00 | 0.34 |
| 647979 | NORAD | ATC13 | Human | Thyroid | ATC | 1.97e-38 | 1.33e+00 | 0.34 |
| 647979 | NORAD | ATC1 | Human | Thyroid | ATC | 1.36e-09 | 1.16e-01 | 0.2878 |
| 647979 | NORAD | ATC2 | Human | Thyroid | ATC | 3.24e-10 | 1.68e+00 | 0.34 |
| 647979 | NORAD | ATC3 | Human | Thyroid | ATC | 1.71e-04 | 6.67e-01 | 0.338 |
| 647979 | NORAD | ATC4 | Human | Thyroid | ATC | 1.79e-48 | 1.40e+00 | 0.34 |
| 647979 | NORAD | ATC5 | Human | Thyroid | ATC | 1.72e-40 | 1.45e+00 | 0.34 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |